KM Research Hub
← 返回论文库
无 KM 图 入排:排除 图源:开放图源暂不可得 入排置信度 0.98

Clesrovimab for Prevention of RSV Disease in Healthy Infants.

Heather J Zar, Eric A F Simões, Shabir A Madhi, Octavio Ramilo, Shelly D Senders, Julie S Shepard, Kamolwish Laoprasopwattana, Jorge Piedrahita, Jose M Novoa, Sergio L Vargas, Marc Dionne, Teresa Jackowska, Enmei Liu, Yasunori Ishihara, Kazushige Ikeda, Ying Zhang, Radha A Railkar, Jeannine Lutkiewicz, Kalpit A Vora, Xiaowei Zang, Brian M Maas, Andrew W Lee, Andrea Guerra, Anushua Sinha, CLEVER (MK-1654-004) Study Group

N Engl J Med 393(13) 1292-1303

PMID40961446
PMCID-
DOI10.1056/NEJMoa2502984
发表日期2025-09-17
入排依据:未发现恶性肿瘤人群证据。
PubMed 未展示 Figure,且无可用 PMC 全文;如需图片,需要从出版社页面获取。
摘要

摘要

BACKGROUND: Clesrovimab is a long-acting investigational monoclonal antibody against site IV of the respiratory syncytial virus (RSV) fusion protein. Data regarding the safety and efficacy of clesrovimab in healthy infants are needed. METHODS: We randomly assigned healthy preterm and full-term infants entering their first RSV season in a 2:1 ratio to receive one intramuscular 105-mg dose of clesrovimab or placebo. The primary efficacy end point was RSV-associated medically attended lower respiratory infection (including at least one indicator of lower respiratory infection or disease severity) through 150 days after injection. A key secondary efficacy end point was RSV-associated hospitalization during the same period. RESULTS: A total of 3614 infants received an injection: 2412 infants received clesrovimab, and 1202 infants received placebo. Through day 150 after injection, RSV-associated medically attended lower respiratory infection occurred in 60 of 2398 infants in the clesrovimab group (incidence rate over 5-month period, 2.6%) and in 74 of 1201 infants in the placebo group (incidence rate over 5-month period, 6.5%), for an efficacy of 60.4% (95% confidence interval [CI], 44.1 to 71.9; P<0.001). RSV-associated hospitalization within 150 days was reported in 9 of 2398 infants in the clesrovimab group and in 28 of 1201 infants in the placebo group, for an efficacy of 84.2% (95% CI, 66.6 to 92.6; P<0.001). Serious adverse events were reported in 278 of 2409 infants (11.5%) in the clesrovimab group and 149 of 1202 infants (12.4%) in the placebo group. CONCLUSIONS: In healthy preterm and full-term infants, a single dose of clesrovimab reduced the incidence of RSV-associated medically attended lower respiratory infection and RSV-associated hospitalization, with a safety profile similar to that of placebo. (Funded by Merck Sharp and Dohme; CLEVER ClinicalTrials.gov number, NCT04767373.).

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。